Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk

Journal of the National Cancer Institute

Volumn 92, Issue 9, 2000, Pages 737-743

  Wu, Xifeng ^a   Yu, He ^b   Amos, Christopher I ^c   Hong, Waun K ^c   Spitz, Margaret R ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^c Univ Texas M D Anderson Cancer C ^*

Author keywords

[No Author keywords available]

Indexed keywords

7,8 DIHYDROXYBENZO[A]PYRENE 9,10 OXIDE; BLEOMYCIN; MUTAGENIC AGENT; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ARTICLE; CANCER RISK; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; GENETIC STABILITY; HUMAN; HUMAN TISSUE; LUNG CARCINOGENESIS; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MUTAGENICITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT;

EID: 0034600258     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.9.737     Document Type: Article

References (45)

1. Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer 1992;65:311-20.
2. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
3. Ankrapp DP, Bevan DR. Insulin-like growth factor-I and human lung fibroblast-derived insulin-like growth factor-I stimulate the proliferation of human lung carcinoma cells in vitro. Cancer Res 1993;53:3399-404.
4. Favoni RE, de Cupis A, Ravera F, Cantoni C, Pirani P. Ardizzoni A, et al. Expression and function of the insulin-like growth factor I system in human non-small-cell lung cancer and normal lung cell lines. Int J Cancer 1994;56: 858-66.
5. Reeve JG, Brinkman A, Hughes S, Mitchell J, Schwander J, Blechen NM. Expression of insulinlike growth factor (IGF) and IGF-binding protein genes in human lung tumor cell lines. J Natl Cancer Inst 1992;84:628-34.
6. Wegmann BR, Schoneberger HJ, Kiefer PE, Jaques G, Brandscheid D, Havemann K. Molecular cloning of IGFBP-5 from SCLC cell lines and expression of IGFBP-4, IGFBP-5 and IGFBP-6 in lung cancer cell lines and primary tumours. Eur J Cancer 1993;29A:1578-84.
7. Noll K, Wegmann BR, Havemann K, Jaques G. Insulin-like growth factors stimulate the release of insulin-like growth factor-binding protein-3 (IGFBP-3) and degradation of IGFBP-4 in nonsmall cell lung cancer cell lines. J Clin Endocrinol Metab 1996;81:2653-62.
8. Quinn KA, Treston AM, Unsworth EJ, Miller MJ, Vos M, Grimley C, et al. Insulin-like growth factor expression in human cancer cell lines. J Biol Chem 1996;271:11477-83.
9. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endoer Rev 1995;16:143-63.
10. Parrizas M, LeRoith D. Insulin-like growth factor-I inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. Endocrinology 1997;138:1355-8.
11. Wang L, Ma W, Markovich R, Lee WL, Wang PH. Insulin-like growth factor I modulates induction of apoptotic signaling in H9C2 cardiac muscle cells. Endocrinology 1998;139: 1354-60.
12. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
13. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
14. Hankinson SE, Willed WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351:1393-6.
15. Yu H, Spitz MR, Mistry J, Gu J. Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999;91:151-6.
16. Hsu TC. Genetic instability in the human population: a working hypothesis. Hereditas 1983;98:1-9.
17. Hsu TC, Johnston DA, Cherry LM, Ramkissoon D, Schantz SP, Jessup JM, et al. Sensitivity to genotoxic effects of bleomycin in humans: possible relationship to environmental carcinogenesis. Int J Cancer 1989;43:403-9.
18. Hsu TC, Spitz MR, Schantz SP, Mutagen sensitivity: a biologic marker of cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1991;1:83-9.
19. Wu X, Gu J, Amos CI, Jiang H, Hong WK, Spitz MR. A parallel study of in vitro sensitivity to benzo[a]pyrene diol epoxide and bleomycin in lung cancer cases and controls. Cancer 1998;1118-27.
20. Wu X, Gu J, Hong WK, Lee JJ, Amos CI, Jiang H, et al. Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. J Natl Cancer Inst 1998;90:1393-9.
21. Spitz MR, Fueger JJ, Beddingfield NA, Annegers JF, Hsu TC, Newell GR, et al. Chromosome sensitivity to bleomycin-induced mutagenesis, an independent risk factor for upper aerodigestive tract cancers. Cancer Res 1989; 49:4626-8.
22. Schantz, SP, Hsu TC, Ainslie N, Moser RP. Young adults with head and neck cancer express increased susceptibility to mutagen-induced chromosome damage. JAMA 1989; 262:3313-5.
23. Spitz MR, Fueger JJ, Halabi S, Schantz SP, Sample D, Hsu TC. Mutagen sensitivity in upper aerodigestive tract cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev 1993;2:329-33.
24. Cloos J, Spitz MR, Schantz SP, Hsu TC, Zhang ZF, Tobi H, et al. Genetic susceptibility to head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:530-5.
25. Spitz MR, Hsu TC, Wu X, Fueger JJ, Amos CI, Roth JA. Mutagen sensitivity as a biological marker of lung cancer risk in African Americans. Cancer Epidemiol Biomarkers Prev 1995;4:99-103.
26. Strom SS, Wu X, Sigurdson AJ, Hsu TC, Fueger JJ, Lopez, J. et al. Lung cancer, smoking patterns, and mutagen sensitivity in Mexican-Americans. J Natl Cancer Inst Monogr 1995; 18:29-33.
27. Wu X, Delclos GL, Annegers FJ, Bondy ML, Honn SE, Henry B, et al. A case-control study of wood dust exposure, mutagen sensitivity, and lung cancer risk. Cancer Epidemiol Biomarkers Prev 1995;4:583-8.
28. Spitz MR, Lippman SM, Jiang H, Lee JJ. Khuri F, Hsu TC, et al. Mutagen sensitivity as a predictor of tumor recurrence in patients with cancer of the upper aerodigestive tract. J Natl Cancer Inst 1998;90:243-5.
29. Wei Q, Spitz MR, Gu J, Cheng L, Xu X, Strom SS, et al. DNA repair capacity correlates with mutagen sensitivity in lymphoblastoid cell lines. Cancer Epidemiol Biomarkers Prev 1996;5:199-204.
30. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res 1990;50: 7415-21.
31. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620-5.
32. Lee DY, Kim SJ, Lee YC. Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients. J Korean Med Sci 1999;14:401-4.
33. German J, editor. Chromosome mutation and neoplasia. New York (NY): Liss: 1983.
34. Maher VM, Ouellette LM, Curren RD, McCormick JJ. Frequency of ultraviolet light-induced mutations is higher in xeroderma pigmentosum variant cells than in normal human cells. Nature 1976;261:593-5.
35. Parrington JM, Delhanty JD, Baden HP. Unscheduled DNA synthesis, u.v.-induced chromosome aberrations and SV 40 transformation in cultured cells from xeroderma pigmentosum. Ann Hum Genet 1971;35:149-60.
36. Setlow RB, Regan JD, German J, Carrier WL. Evidence that xeroderma pigmentosum cells do not perform the first step in the repair of ultraviolet damage to their DNA. Proc Natl Acad Sci U S A 1969;64:1035-41.
37. Cleaver JE. Detective repair replications of DNA in xeroderma pigmentosum. Nature 1968;218:652-6.
38. Paterson MC, Smith PJ. Ataxia telangiectasia: an inherited human disorder involving hypersensitivity to ionizing radiation and related DNA-damaging chemicals. Annu Rev Genet 1979;13:291-318.
39. Xu YJ, Kim EY, Demple B. Excision of C-4′-oxidized deoxyribose lesions from double-stranded DNA by human apurinic/apyrimidinic endonuclease (Ape I protein) and DNA polymerase beta. J Biol Chem 1998;273:28837-44.
40. Dar ME, Winters TA, Jorgensen TJ. Identification of detective illegitimate recombinational repair of oxidatively-induced DNA double-strand breaks in ataxia-telangiectasia cells. Mutat Res 1997;384:169-79.
41. Shou M, Harvey RG, Penning TM. Reactivity of benzo[a]pyrene-7,8-dione with DNA. Evidence for the formation of deoxyguanosine adducts. Carcinogenesis 1993;14:475-82.
42. Tang MS, Pierce JR, Doisy RP, Nazimiee ME, MacLeod MC. Differences and similarities in the repair of two benzo[a]pyrene diol epoxide isomers induced DNA adducts by uvrA, uvrB, and uvrC gene products. Biochemistry 1992; 31:8429-36.
43. Mazzoccoli G, Giuliani A, Bianco G, De Cata A, Balzanelli M, Carella AM, et al. Decreased serum levels of insulin-like growth factor (IGF)-I in patients with lung cancer: temporal relationship with growth hormone (GH) levels. Anticancer Res 1999;19:1397-9.
44. Bruning PF, Van Doom J, Bonfrer JM, Van Noord PA, Korse CM, Linders TC, et al. Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable premenopausal breast cancer. Int J Cancer 1995; 62:266-70.
45. Wolk A, Mantzoros CS, Anderson SO, Bergstrom R, Signorello LB, Lagiou P, et al. Insulin-like growth factor I and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998;90:911-5.